Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7846815 | 1.00 | TACR1 (0.68) | TACR1TACR3 | |
| SCHEMBL7062087 | 0.94 | TACR1 (0.76) | TACR1TACR3 | |
| SCHEMBL7853075 | 0.92 | TACR1 (0.59) | TACR1TACR3 | |
| SCHEMBL7067956 | 0.91 | TACR1 (0.67) | TACR1TACR3 | |
| SCHEMBL7066516 | 0.90 | TACR1 (0.64) | TACR1TACR3 | |
| SCHEMBL7846970 | 0.88 | TACR1 (0.65) | TACR1TACR3 | |
| SCHEMBL7067244 | 0.88 | TACR1 (0.62) | TACR1TACR3 | |
| SCHEMBL7062350 | 0.85 | TACR1 (0.76) | TACR1TACR3 | |
| SCHEMBL7067242 | 0.85 | TACR1 (0.62) | TACR1TACR3 | |
| SCHEMBL7847443 | 0.85 | TACR1 (0.62) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6472418-B1 | Non-peptide NK1 receptors antagonists | WARNER-LAMBERT COMPANY | 2002-10-29 | — | — | US | claimed |
| US-6436914-B1 | TREATING DIABETES, OBESITY, DEPRESSION, ACHALASIA OR INTESTINAL HYPERMOTILITY DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-20 | — | — | US | claimed |
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | SHER PHILIP M (US) | 2002-02-28 | — | — | US | claimed |
| US-20030065007-A1 | NK1 receptor antagonists | CRESWELL MARK WALLACE (US) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065007-A1 | NK1 receptor antagonists | HRH1, HRH4, HRH2 | TACR1 18/4885TACR3 141/4885 |
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | ADRB3, ADRB1, ADRA1A | TACR1 245/4885TACR3 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.